Prevalence of comorbidities and their influence on blood pressure goal attainment in geriatric patients

American Journal of Geriatric Cardiology

Volumn 16, Issue 1, 2007, Pages 24-29

  Bisognano, John D ^a   Townsend, Kevin A ^b,c   Skyles, Amy J ^d   Samuels, Kiela M ^c,d  

^a UNIVERSITY OF ROCHESTER   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GERIATRIC PATIENT; GOAL ATTAINMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREVALENCE; PRIORITY JOURNAL; SYSTOLIC HYPERTENSION; TREATMENT RESPONSE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; GERIATRIC ASSESSMENT; HYPERTENSION; MIDDLE AGED; PATIENT CARE PLANNING; PATIENT COMPLIANCE; PHYSIOLOGY; RETROSPECTIVE STUDY; STANDARD; TREATMENT OUTCOME; UNITED STATES;

AGED; AGED, 80 AND OVER; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; COMORBIDITY; DIABETES COMPLICATIONS; FEMALE; GERIATRIC ASSESSMENT; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MALE; MICHIGAN; MIDDLE AGED; NEW YORK; PATIENT CARE PLANNING; PATIENT COMPLIANCE; PREVALENCE; RETROSPECTIVE STUDIES; SODIUM CHLORIDE SYMPORTER INHIBITORS; TREATMENT OUTCOME;

EID: 33947517813     PISSN: 10767460     EISSN: 1751715X     Source Type: Journal    
DOI: 10.1111/j.1076-7460.2007.05543.x     Document Type: Article

References (26)

1. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289:2560-2572.
2. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey. 1988-1991. Hypertension. 1995;25:305-313.
3. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199-206.
4. US Census Bureau. The 65 Years and Older Population: 2000. Washington, DC: US Census Bureau; 2001.
5. Implications of the systolic hypertension in the elderly program. The Systolic Hypertension in the Elderly Program Cooperative Research Group. Hypertension. 1993;21:335-343.
6. Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 2001;37:869-874.
7. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: Data from the health examination surveys, 1960 to 1991. Hypertension. 1995;26:60-69.
8. National Center for Health Statistics. Health Promotion and Disease Prevention United States, 1990. Hyattsville, MD: Public Health Service; 1993: 33. Dept of Health and Human Services publication 93-1513.
9. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet. 2002;360:1903-1913.
10. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published corrections appear in JAMA. 2003;289:178 and JAMA. 2004;291:2196]. JAMA. 2002;288:2981-2997.
11. Black HR, Elliott WJ, Neaton JN, et al, for the CONVINCE Research Group. Baseline characteristics and early blood pressure control in the CONVINCE Trial. Hypertension. 2001;37:12-18.
12. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287:1003-1010.
13. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Lancet. 2000;356:1955-1964.
14. National Kidney Foundation Guideline. K/DOQI clinical practice guidelines for chronic kidney disease. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis. 2002;39(suppl 2):S1-S246.
15. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289:2073-2082.
16. Yusuf S, Sleight P, Poque J, et al, for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
17. Pitt B, Remme W, Zannad F, et al, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
18. UK Prospective Diabetes Study Group. Efficacy of atenolol and captoril in reducing risk of marcrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317:713-720.
19. Wright JT Jr, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med. 2002;162:1636-1643.
20. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet. 2002;359:995-1003.
21. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-2446.
22. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
23. Wannemacher AJ, Schepers GP, Townsend KA. Antihypertensive medication compliance in a Veterans Affairs Healthcare System. Ann Pharmacother. 2002;36:986-991.
24. Degli Esposti ED, Sturani A, Di Martino M, et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens. 2002;16:439-444.
25. Staessen JA, Fagard R, Thijs L, et al, on behalf of the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-764.
26. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: Current outcomes and control in the community. JAMA. 2005;294:466-472.